Veritas In Silico Inc.
| Code | Sector | Market | 
|---|---|---|
| 130A | Pharmaceuticals | Growth | 
| Date of listing approval | 2024/01/05 | 
|---|---|
| Expected Date | 2024/02/08 | 
| Lead Underwriter | Mizuho Securities Co., Ltd | 
| Description | 
| Listed Shares(total) | 920,000 | 
|---|---|
| Trading Unit | 100 | 
| New Shares | 800,000 | 
| Existing Shares | 120,000¡Êonly O.A.¡Ë | 
| Shares Outstanding | PreIPO 5,501,314.00 | 
| PostIPO 6,301,314.00 | |
| Paid Up Capital | PreIPO Y90,000,000 | 
| PostIPO Y312,548,000 | |
| Expected Pricing Date | 2024/01/23 | 
| Book Building Start | 2024/01/24 | 
| Book Building End | 2024/01/30 | 
| Fix Date | 2024/01/31 | 
| Offering Starts | 2024/02/01 | 
| Offering Ends | 2024/02/06 | 
| Expect Pricing | Y800-Y1,000 | 
| Notional PER (based on previous period) | -31.13--38.91 | 
| Notional PER(based on results forecast) | 141.09-176.37 | 
| Offering Price | Y1,000 | 
| Offering Price PER (based on previous period) | 141.09-176.37 | 
| Offering Price PBR (based on previous period) | 3.57 | 
| Offering Price PER (based on results forecast) | 176.37 | 
| Use of Funds Raised | 
Financial Data
Units:Y1,000
| Fiscal Year End:2020/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 13,326 | 
| Current Profit | - | -297,034 | 
| Net Profit | - | -297,905 | 
| Net Assets | - | 516,291 | 
| Fiscal Year End:2021/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 59,330 | 
| Current Profit | - | -240,082 | 
| Net Profit | - | -232,319 | 
| Net Assets | - | 1,683,971 | 
| Fiscal Year End:2022/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 178,801 | 
| Current Profit | - | -138,455 | 
| Net Profit | - | -141,381 | 
| Net Assets | - | 1,542,590 | 
| Recent Quarter 2023/09 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 279,251 | 
| Current Profit | - | 37,888 | 
| Net Profit | - | 35,750 | 
| Net Assets | - | 1,578,341 | 
| Results Forecast 2023/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 359,000 | 
| Current Profit | - | 34,000 | 
| Net Profit | - | 31,000 | 
| Net Assets | - | - | 
Per Share Units:Y1
| Fiscal Year End:2020/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - | 
| Equity | -68.00 | 117.84 | 
| Fiscal Year End:2021/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - | 
| Equity | -51.92 | 306.10 | 
| Fiscal Year End:2022/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - | 
| Equity | -25.70 | 280.40 | 
| Fiscal Year End:Recent Quarter 2023/09 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | ||
| Net Earning | - | 6.50 | 
| Equity | - | - | 
| Fiscal Year End:Results Forecast 2023/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | 5.67 | 
| Equity | - | - | 
Comment
| ¢£Over allotment(120,000¡Ë | 
Consolidated Subsidiaries
| Name | Address | 
|---|
Underwriters
| Allocation | Underwriter | Tel | 
|---|---|---|
| 0% | Nomura | 03-3211-1811 | 
| 93.3% | Mizuho Securities Co., Ltd | 03-5208-3210 | 
| 2% | SMBC Nikko Securities Inc. | 03-5644-3111 | 
| 2% | Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. | 03-6213-8500 | 
| 1.1% | Rakuten Securities Holdings, Inc. | 03-6406-2681 | 
| 1.1% | Matsui Securities Co., Ltd | 03-5216-0606 | 
| 0.5% | Akatsuki Securities,Inc | 03-5641-7800 | 
Data
| Date of incorporation | 2016/11/17 | 
|---|---|
| Company address | Tokyo 141-0031 | 
| Telephone | 03-6421-7537 | 
| President | |
| Homepage | https://www.veritasinsilico.com/ | 
| Auditor | Toyo Audit | 
| Major Shareholders | |
|---|---|
| Shareholder Name | Ratio | 
| 86.62% | |
| 23.33% | |
| 11.96% | |
| 9.10% | |
| 8.39% | |
| 8.15% | |
| 5.63% | |
| 4.88% | |
| 4.68% | |
| 3.93% | |
| 3.40% | |
| Number of Employees | 15 as of 2023/11/30 | 
|---|---|
| Birth Date of Representative | 1972/06/07 | 
